One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Ischaemic heart disease: antithrombotic treatment and new therapeutic targets
Filippo Crea
doi : 10.1093/eurheartj/ehac816
European Heart Journal, Volume 44, Issue 4, 21 January 2023, Pages 239–242
The Journal Citation Indicator: what is the relevance of this new metric?
Filippo Crea, Tomasz Guzik, Alexandra Frances Kavaney
doi : 10.1093/eurheartj/ehac795
European Heart Journal, Volume 44, Issue 4, 21 January 2023, Pages 243–244
Too hot to handle? The truth about the effects of extreme heat on cardiovascular health
Judith Ozkan
doi : 10.1093/eurheartj/ehac554
European Heart Journal, Volume 44, Issue 4, 21 January 2023, Pages 245–247
Young at heart: a DNA methylation's tale
Alessia Mongelli, Antonella Farsetti, Carlo Gaetano
doi : 10.1093/eurheartj/ehac654
European Heart Journal, Volume 44, Issue 4, 21 January 2023, Pages 248–250,
Coronary interventions 2021: insights from the National Societies of Cardiology Journals of the European Society of Cardiology
Jean-Jacques Monsuez, Plamen Gatzov, Ignacio Ferreira-Gonzalez, Fernando Alfonso,
doi : 10.1093/eurheartj/ehac679
European Heart Journal, Volume 44, Issue 4, 21 January 2023, Pages 251–253
Protection and delay of aortic complications in the Marfan syndrome: a new indication for angiotensin receptor blockers on top of β blockers
Daniela Pedicino, Massimo Volpe
doi : 10.1093/eurheartj/ehac685
European Heart Journal, Volume 44, Issue 4, 21 January 2023, Pages 254–255
The year in cardiovascular medicine 2022: the top 10 papers in dyslipidaemias
Lale Tokgozoglu, Carl Orringer, Alberico Catapano
doi : 10.1093/eurheartj/ehac750
European Heart Journal, Volume 44, Issue 4, 21 January 2023, Pages 256–258
The year in cardiovascular medicine 2022: the top 10 papers in interventional cardiology
Emanuele Barbato, Margaret McEntegart, Tommaso Gori
doi : 10.1093/eurheartj/ehac778
European Heart Journal, Volume 44, Issue 4, 21 January 2023, Pages 259–261
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis
Felicita Andreotti, Tobias Geisler, Jean-Philippe Collet, Bruna Gigante, Diana A Gorog, Sigrun Halvorsen, Gregory Y H Lip, Joao Morais, Eliano Pio Navarese, Carlo Patrono, Bianca Rocca, Andrea Rubboli, Dirk Sibbing, Robert F Storey, Freek W A Verheugt, Gemma Vilahur
doi : 10.1093/eurheartj/ehac515
European Heart Journal, Volume 44, Issue 4, 21 January 2023, Pages 262–279
The first international guidance on antithrombotic therapy in the elderly came from the European Society of Cardiology Working Group on Thrombosis in 2015.
Factor XI inhibitors: cardiovascular perspectives
Raffaele De Caterina, Domenico Prisco, John W Eikelboom
doi : 10.1093/eurheartj/ehac464
European Heart Journal, Volume 44, Issue 4, 21 January 2023, Pages 280–292
Anticoagulants are the cornerstone for prevention and treatment of thrombosis but are not completely effective, and concerns about the risk of bleeding continue to limit their uptake.
Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis
Eri Toda Kato, David A Morrow, Jianping Guo, David D Berg, Michael A Blazing, Erin A Bohula, Marc P Bonaca, Christopher P Cannon, James A de Lemos, Robert P Giugliano, Petr Jarolim, Tibor Kempf, L Kristin Newby, Michelle L O’Donoghue, Marc A Pfeffer, Nader Rifai, Stephen D Wiviott, Kai C Wollert, Eugene Braunwald, Marc S Sabatine
doi : 10.1093/eurheartj/ehac577
European Heart Journal, Volume 44, Issue 4, 21 January 2023, Pages 293–300
Levels of growth differentiation factor 15 (GDF-15), a cytokine secreted in response to cellular stress and inflammation, have been associated with multiple types of cardiovascular (CV) events. However, its comparative prognostic performance across different presentations of atherosclerotic cardiovascular disease (ASCVD) remains unknown.
Growth differentiation factor 15: a biomarker searching for an indication
Christian Mueller, Tamar S Muench-Gerber, Rudolf A de Boer
doi : 10.1093/eurheartj/ehac681
European Heart Journal, Volume 44, Issue 4, 21 January 2023, Pages 301–303
Vinculin phosphorylation impairs vascular endothelial junctions promoting atherosclerosis
Yu-Tsung Shih, Shu-Yi Wei, Jin-Hua Chen, Wei-Li Wang, Hsin-Yi Wu, Mei-Cun Wang, Chia-Yu Lin, Pei-Lin Lee, Chih-Yuan Lin, Hung-Che Chiang, Yu-Ju Chen, Shu Chien, Jeng-Jiann Chiu
doi : 10.1093/eurheartj/ehac647
European Heart Journal, Volume 44, Issue 4, 21 January 2023, Pages 304–318
Atherosclerosis preferentially develops in arterial branches and curvatures where vascular endothelium is exposed to disturbed flow. In this study, the effects of disturbed flow on the regulation of vascular endothelial phosphoproteins and their contribution to therapeutic application in atherogenesis were elucidated.
Vinculin phosphorylation modulates endothelial cell permeability: a new target for cardiovascular disease?
Fabrizia Bonacina, Giuseppe Danilo Norata
doi : 10.1093/eurheartj/ehac704
European Heart Journal, Volume 44, Issue 4, 21 January 2023, Pages 319–321
Safety of non-vitamin K antagonist oral anticoagulants: concerns in patients with atrial fibrillation and glomerular hyperfiltration?
Safety of non-vitamin K antagonist oral anticoagulants: concerns in patients with atrial fibrillation and glomerular hyperfiltration?
doi : 10.1093/eurheartj/ehac450
European Heart Journal, Volume 44, Issue 4, 21 January 2023, Pages 322–325
First-in-human transcatheter endocardial alginate-hydrogel implantation for the treatment of heart failure
Bo Wang, Randall J Lee, Ling Tao
doi : 10.1093/eurheartj/ehac671
European Heart Journal, Volume 44, Issue 4, 21 January 2023, Page 326
Hypertrophic cardiomyopathy and left ventricular non-compaction cardiomyopathy: two in one
Beshoy Gabra, Nandan S Anavekar, Philip Haaf
doi : 10.1093/eurheartj/ehac718
European Heart Journal, Volume 44, Issue 4, 21 January 2023, Page 327
